Your AI-Trained Oncology Knowledge Connection!

Commentary

Video

Additional Potential Roles for Mirvatuximab Soravtansine and Other ADCs in Ovarian Cancer

Author(s):

Floortje J. Backes, MD

Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Hyun-Woong Cho, MD, PhD, Department of Obstetrics and Gynecology, Korea University College of Medicine
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss the evolution of treatment for metastatic hormone-sensitive prostate cancer.
Kathleen N. Moore, MD, MS
Emily M. Hinchcliff, MD, MPH, an assistant professor of obstetrics and gynecology (gynecologic oncology) at the Feinberg School of Medicine at Northwestern Medicine
Stéphanie Lheureux, MD, PhD, clinician investigator, Cancer Clinical Research Unit, Princess Margaret Cancer Centre
Related Content
Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.
March 22nd 2025

The OncFive: Top Oncology Articles for the Week of 3/16

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Image credit: Crystal light - stock.adobe.com
March 18th 2025

Abemaciclib/Hormonal Therapy Combo Yields Clinical Activity in LGSOC/EEC

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Platinum-Resistant Ovarian Cancer | Image credit: © Sebastian Kaulitzki - stock.adobe.com
March 17th 2025

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer

Ovarian Cancer | Image Credit: © Katsyarina – stock.adobe.com
March 17th 2025

Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer